
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva is positioned for strong growth due to increasing expectations for Giapreza, which is addressing a significant unmet need in the management of septic shock, supported by improved access and potential updates to treatment guidelines. The commercial momentum is further highlighted by Xacduro's rapid sales growth, with projected revenues reaching $21.1 million in 2024 and an impressive run rate of $95.3 million by 3Q25. Additionally, the company benefits from durable patent protection, which enhances its revenue outlook and reinforces the positive sentiment around its expanding healthcare asset portfolio.
Bears say
Innoviva Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to high mortality rates associated with infections like MRSA, which complicate the market potential for its healthcare assets. The company is also at risk of failing to successfully commercialize its marketed products and launch new drugs, such as ZEVTERA and zoliflodacin, amidst a landscape of rising antibiotic resistance that impacts treatment efficacy. Furthermore, there are concerns regarding declining royalty revenues from respiratory products due to potential generic erosion and broader macroeconomic risks that could adversely affect the company's financial stability.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares